debrisoquin has been researched along with Lymphoma in 1 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.
Excerpt | Relevance | Reference |
---|---|---|
"101 white British adults with Hodgkin's disease or non-Hodgkin's lymphoma were phenotyped for acetylation status using dapsone and for oxidation status with debrisoquine prior to treatment." | 3.67 | Acetylation and oxidation phenotypes in malignant lymphoma. ( Harper, PG; Philip, PA; Rogers, HJ, 1987) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Philip, PA | 1 |
Rogers, HJ | 1 |
Harper, PG | 1 |
1 other study available for debrisoquin and Lymphoma
Article | Year |
---|---|
Acetylation and oxidation phenotypes in malignant lymphoma.
Topics: Acetylation; Adult; Aged; Dapsone; Debrisoquin; Female; Hodgkin Disease; Humans; Lymphoma; Lymphoma, | 1987 |